Skip to main content

Table 3 Survival Characteristics of re-infection in the treatment groups

From: An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours)

Group

Number of cases

Number of events

Number censored

Mean survival time in days (95% C.I)

AS/SMP

229

13

216(94.3%)

27.541 (27.249-27.834)

AS/AQ

238

4

234(98.3%)

27.882 (27.695-28.070)